| Literature DB >> 7531333 |
N Kuno1, K Kurimoto, M Fukushima, T Hayakawa, T Shibata, T Suzuki, A Sakakibara, N Katada, S Nakano, T Takayama.
Abstract
In 403 patients suspected of having pancreatic cancer, we prospectively studied a combination assay of various serum tumor markers: CA19-9, DUPAN2, tissue polypeptide antigen, elastase 1, gamma-glutamyltranspeptidase, lactate dehydrogenase, lipase, amylase, and alkaline phosphatase. The diagnostic value of each marker was compared with a multivariate analysis (computer-aided multivariate and pattern analysis system for pancreatic cancer examine-1: CAMPAS-PX1). Pancreatic cancer was subsequently identified in 47 patients. CAMPAS-PX1 had higher negative in health and positive predictability than those of each marker used alone in the diagnosis of pancreatic cancer. CAMPAS-PX1 proved the most effective marker for diagnosing pancreatic cancer, but in terms of its cost/benefit ration CAMPAS-PX1 was not superior to CA19-9 used alone. In this prospective trial, we experienced poor generalizability in the statistical models (CAMPAS-PX1). We believe that selection bias was present in samples used for model building. Based on this study a new model has been designed.Entities:
Mesh:
Substances:
Year: 1994 PMID: 7531333 DOI: 10.1097/00006676-199411000-00009
Source DB: PubMed Journal: Pancreas ISSN: 0885-3177 Impact factor: 3.327